Evolent Health (NYSE:EVH) Shares Cross Below Fifty Day Moving Average - What's Next?

Evolent Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Evolent Health shares fell below their 50-day moving average of $4.23, trading as low as $3.89 and last at $3.945.
  • Analysts remain broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $6.04, with 10 Buy, three Hold and one Sell rating.
  • In its latest quarter, Evolent reported EPS of $0.06, matching estimates, while revenue of $725.37 million narrowly missed consensus but rose 51.3% year over year.
  • Five stocks we like better than Evolent Health.

Evolent Health, Inc (NYSE:EVH - Get Free Report)'s share price passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.23 and traded as low as $3.89. Evolent Health shares last traded at $3.9450, with a volume of 3,097,204 shares trading hands.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on EVH shares. TD Cowen lifted their price target on Evolent Health from $5.00 to $6.00 and gave the stock a "buy" rating in a report on Monday, August 17th. Oppenheimer increased their price objective on Evolent Health from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, November 6th. Citigroup raised Evolent Health from a "neutral" rating to a "buy" rating and cut their target price for the stock from $6.75 to $6.00 in a research report on Monday, August 10th. Canaccord Genuity Group cut their target price on Evolent Health from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. boosted their target price on Evolent Health from $5.00 to $6.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 18th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $6.04.

Get Our Latest Stock Analysis on EVH

Evolent Health Price Performance

The company has a debt-to-equity ratio of 2.60, a quick ratio of 1.26 and a current ratio of 1.26. The stock's 50-day moving average is $4.23 and its 200 day moving average is $3.93. The stock has a market capitalization of $446.22 million, a PE ratio of -0.87 and a beta of 1.03.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.06. The firm had revenue of $725.37 million for the quarter, compared to the consensus estimate of $727.06 million. Evolent Health had a negative return on equity of 6.07% and a negative net margin of 21.67%. The firm's quarterly revenue was up 51.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.05 EPS. As a group, equities analysts expect that Evolent Health, Inc will post -0.25 earnings per share for the current year.

Insider Transactions at Evolent Health

In related news, President Daniel Mccarthy sold 65,892 shares of the firm's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $5.00, for a total value of $329,460.00. Following the completion of the sale, the president owned 655,133 shares in the company, valued at $3,275,665. This trade represents a 9.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Evolent Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in EVH. Algert Global LLC raised its stake in shares of Evolent Health by 265.5% during the 3rd quarter. Algert Global LLC now owns 2,399,203 shares of the technology company's stock worth $8,373,000 after buying an additional 1,742,740 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of Evolent Health by 127.3% in the 3rd quarter. Virtu Financial LLC now owns 52,731 shares of the technology company's stock valued at $184,000 after buying an additional 29,537 shares during the period. Marshall Wace LLP boosted its stake in shares of Evolent Health by 56.0% in the third quarter. Marshall Wace LLP now owns 5,323,524 shares of the technology company's stock valued at $18,579,000 after buying an additional 1,910,279 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Evolent Health in the third quarter valued at approximately $394,000. Finally, 49 Wealth Management LLC purchased a new stake in shares of Evolent Health in the third quarter valued at approximately $36,000.

About Evolent Health

(Get Free Report)

Evolent Health, Inc. provides technology-enabled services to health plans and healthcare providers in the United States. The company helps clients manage care, coordinate services and support the delivery of healthcare, particularly for people with complex medical needs. Its offerings include specialty care management programs, clinical and administrative services, and technology that supports care decisions and operations. Evolent has focused on areas such as oncology, cardiology, musculoskeletal care and behavioral health.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Evolent Health Right Now?

Before you consider Evolent Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.

While Evolent Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines